Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Tyndall, 2010, Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database, Ann Rheum Dis, 69, 1809, 10.1136/ard.2009.114264 Nihtyanova, 2014, Prediction of pulmonary complications and long-term survival in systemic sclerosis, Arthritis Rheumatol, 66, 1625, 10.1002/art.38390 Tashkin, 2006, Cyclophosphamide versus placebo in scleroderma lung disease, N Engl J Med, 354, 2655, 10.1056/NEJMoa055120 Goldin, 2009, Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study, Chest, 136, 1333, 10.1378/chest.09-0108 Kim, 2011, Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosophamide, Eur Radiol, 21, 2455, 10.1007/s00330-011-2223-2 Tashkin, 2007, Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease, Am J Respir Crit Care Med, 176, 1026, 10.1164/rccm.200702-326OC Furst, 2011, Adverse events during the Scleroderma Lung Study, Am J Med, 124, 459, 10.1016/j.amjmed.2010.12.009 Martinez, 2006, Cyclophosphamide for scleroderma lung disease, N Engl J Med, 354, 2707, 10.1056/NEJMe068095 Staatz, 2014, Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update, Arch Toxicol, 88, 1351, 10.1007/s00204-014-1247-1 Hahn, 2012, American college of rheumatology guidelines for screening, treatment and management of lupus nephritis, Arthritis Care Res, 64, 797, 10.1002/acr.21664 Nihtyanova, 2007, Mycophenolate mofetil in diffuse cutaneous systemic sclerosis–a retrospective analysis, Rheumatology (Oxford), 46, 442, 10.1093/rheumatology/kel244 Gerbino, 2008, Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease, Chest, 133, 455, 10.1378/chest.06-2861 Swigris, 2006, Mycophenolate mofetil is safe, well tolerated and preserves lung function in patients with connective tissue disease-related interstitial lung disease, Chest, 130, 30, 10.1016/S0012-3692(15)50949-5 Zamora, 2008, Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease, Respir Med, 102, 150, 10.1016/j.rmed.2007.07.021 Simeón-Aznar, 2011, Effect of mycophenolate sodium in scleroderma-related interstitial lung disease, Clin Rheumatol, 30, 1393, 10.1007/s10067-011-1823-1 Fischer, 2013, Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease, J Rheumatol, 40, 640, 10.3899/jrheum.121043 Masi, 1980, Preliminary criteria for the classification of systemic sclerosis (scleroderma), Arthritis Rheumatol, 23, 581, 10.1002/art.1780230510 Mahler, 1984, The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes, Chest, 85, 751, 10.1378/chest.85.6.751 Clements, 1993, Skin thickness score in systemic sclerosis (SSc): An assessment of inter-observer variability in three independent studies, J Rheumatol, 20, 1892 Mahler, 2004, Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD, COPD, 1, 165, 10.1081/COPD-120030829 Kim, 2010, A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients, Clin Exp Rheumatol, 5, S26 Roth, 2011, Predicting lung function and treatment outcomes in scleroderma-related interstitial lung disease, Arthritis Rheum, 63, 2797, 10.1002/art.30438 Li, 2012, Joint analysis of bivariate longitudinal ordinal outcomes and competing risks survival times with nonparametric distributions for random effects, Stat Med, 31, 1707, 10.1002/sim.4507 Elashoff, 2008, A joint model for longitudinal measurements and survival data in the presence of multiple failure types, Biometrics, 64, 762, 10.1111/j.1541-0420.2007.00952.x Tashkin, 2016, Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis, Ann Rheum Dis, 75, 374, 10.1136/annrheumdis-2014-206076 Khanna, 2006, Minimally important difference in diffuse systemic sclerosis: results of the D-penicillamine study, Ann Rheum Dis, 65, 1325, 10.1136/ard.2005.050187 Khanna, 2009, Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial—results from the Scleroderma Lung Study, Rheumatology (Oxford), 48, 1537, 10.1093/rheumatology/kep284 Zheng, 2010, The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats, Rheumatol Int, 30, 341, 10.1007/s00296-009-0966-8 Saketkoo, 2015, Observations from the pulmonary hypertension recognition and outcomes in scleroderma (Pharos) Cohort, Ann Rheum Dis, 74, 820, 10.1136/annrheumdis-2015-eular.3483